Company began 2018 with approximately $182 Million in cash and investments Pro-forma year-end 2017 cash and investments of approximately $372 Million , including net proceeds from the recently completed public offering Announced over-enrollment in the ARTEMIS Phase 3 trial Additional AR101 clinical
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
— Late-Breaking Oral Presentation by Dr. Stacie Jones — — PALISADE Results Expected to Provide Core Element of BLA Submission by Year-End 2018 — BRISBANE, Calif. & ORLANDO, Fla. --(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 2, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the evening of March 4, 2018 , at the joint
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public offering of 5,500,000
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 20, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of
Landmark 554-patient Phase 3 study met the primary efficacy endpoint, as 67.2% of AR101 patients ages 4–17 tolerated at least a 600-mg dose of peanut protein in the exit food challenge, compared to 4.0% of placebo patients (p
— New Members Join International Board of Leading Academic Experts in Allergy and Immunology — — Prof. du Toit Is Lead Author of Landmark LEAP and LEAP-On Studies on Prevention of Peanut Allergy in Young Children — — Dr. Shreffler Is a Renowned Expert on Immunologic Mechanisms of Food Allergy —
